XML 142 R96.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Principal alliances - Agreements on the commercialization of Beyfortus™ (nirsevimab, previously MEDI8897) in the US (Details) - EUR (€) € in Millions |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 09, 2023 | Jul. 31, 2023 | Nov. 30, 2022 | Mar. 31, 2017 | Sep. 30, 2019 | Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Other non-current liabilities |  |  |  |  |  | € 2,340 | € 2,340 | € 519 | € 291
Antibodies Collaboration agreement | AstraZeneca |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Collaboration agreements, upfront payment |  |  |  | € 120 |  |  |  |  |
Collaboration agreements, development milestone payment |  |  |  |  | € 30 |  |  |  |
Collaboration agreements, regulatory milestone payment |  | € 65 | € 25 |  |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  | 375 | 375 |  |
Accruals |  |  |  |  |  | 25 | € 25 |  |
Percentage of development costs arising from commercial operations |  |  |  |  |  |  | 50.00% |  |
Antibodies Collaboration agreement | AstraZeneca | Other intangible assets excluding software |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Acquisitions and other increases | € 1,600 |  |  |  |  |  |  |  |
Antibodies Collaboration agreement | AstraZeneca | Major territories |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  |  | 50.00% |  |
Antibodies Collaboration agreement | AstraZeneca | Other territories |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Percentage of net sales arising from commercial operations |  |  |  |  |  |  | 25.00% |  |
Antibodies Collaboration agreement | AstraZeneca | China |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations | 50.00% |  |  |  |  |  |  |  |
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |
Other non-current liabilities | € 1,600 |  |  |  |  | 1,960 | € 1,960 |  |
Increase through remeasurement of financial liability |  |  |  |  |  | € 541 |  |  |

X
- Definition The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_Accruals
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherNoncurrentLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreements, Development Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsDevelopmentMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Regulatory Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Upfront Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsUpfrontPayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Related To Milestone Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure of Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Development Costs Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Net Sales Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfNetSalesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Profits Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |